News - Zelboraf

Filter

Current filters:

Zelboraf

Popular Filters

Roche’s Zelboraf improves survival in melanoma patients with brain metastases

Roche’s Zelboraf improves survival in melanoma patients with brain metastases

21-11-2013

Zelboraf (vemurafenib), an already marketed cancer drug from Swiss pharma major Roche (ROG: SIX), has…

EuropeOncologyPharmaceuticalResearchRocheZelboraf

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments

01-11-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

Scotland denies access to Roche skin cancer drug Zelboraf, but OKs Novartis' Gilenya

11-09-2012

Swiss drug major Roche (ROG SIX) says it is "extremely disappointed" that the Scottish Medicines Consortium…

EuropeGilenyaHealthcareNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRocheZelboraf

Yervoy and Zelboraf rapidly penetrating metastatic patient population in USA and Europe

23-08-2012

In the USA and Europe there is strong physician desire for new therapies for the treatment of early stage…

Bristol-Myers SquibbEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalRocheYervoyZelboraf

UK's NICE delays decision on Roche's Zelboraf, asking for more information

10-08-2012

UK health care watchdog the National Institute for Health and Clinical Excellence (NICE) today (August…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

MEK inhibitors: new weapon in the fight against melanoma

24-06-2012

Cancer cell signaling has long been an attractive target for oncology drug development. Increased activation…

dabrafenibGlaxoSmithKlineOncologyPharmaceuticalResearchRochetrametinibZelboraf

UK's NICE denies NHS access to Roche melanoma drug Zelboraf

15-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

Roche’s Zelboraf nearly doubles survival in majority of MM patients

23-02-2012

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the USA and Australia…

OncologyPharmaceuticalResearchRocheZelboraf

European approval for Roche skin cancer drug Zelboraf

21-02-2012

Swiss drug major Roche (ROG: SIX) says that the European Commission has approved Zelboraf (vemurafenib)…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

EMA recommends approval of Roche’s Zelboraf

19-12-2011

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

Malignant melanoma drug market to grow more than seven-fold to $1.5 billion in 2020

05-10-2011

The market for malignant melanoma drugs is forecast to expand more than seven-fold over the next decade,…

dabrafenibGlobalMarkets & MarketingOncologyPharmaceuticaltrametinibYervoyZelboraf

New drivers of oncology market - Yervoy, Zelboraf, Xalkori and Zytiga - assessed

15-09-2011

The cancer marketplace is going through a paradigm shift with new product launches and competitive promotion…

Markets & MarketingOncologyPharmaceuticalXalkoriYervoyZelborafZytiga

Roche’s Zelboraf and companion diagnostic for late-stage melanoma cleared in USA

18-08-2011

Swiss drug major Roche (ROG: SIX) yesterday received US Food and Drug Administration approval for Zelboraf…

North AmericaOncologyPharmaceuticalRegulationRochevemurafenibZelboraf

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top